Independent editorial coverage · not a pharmacy
← All news
SafetyNovember 12, 2026 · 3 min read

FDA Orders a Class-Wide GLP-1 Label Warning on a Rare Cause of Vision Loss

The FDA is requiring makers of all approved GLP-1 receptor agonists, including semaglutide and tirzepatide, to add a warning about a potential increased risk of NAION, a rare optic nerve condition. The agency said a causal link has not been established.

By the GLP Semaglutide editorial team · Last updated November 12, 2026

A stethoscope resting on a medical chart
Photo illustration

The U.S. Food and Drug Administration said on November 9 that it is requiring the makers of all approved GLP-1 receptor agonist medicines to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their labels. NAION is a rare condition that can cause sudden, painless loss of vision in one eye, sometimes permanently.

Which drugs are affected

The FDA's list of approved GLP-1 receptor agonists includes Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Victoza and Saxenda (liraglutide), Trulicity (dulaglutide), the combination products Xultophy and Soliqua, and Lilly's oral Foundayo (orforglipron). BioSpace counted 12 marketed products that will need the change. According to CNBC, the agency said NAION cases have been reported for all currently marketed GLP-1 products.

What the data showed

The FDA said it ran a meta-analysis of 126 randomized trials covering 134,253 patients, because individual trials had too few or no cases to draw conclusions. It identified 15 probable NAION events: 10 among patients on GLP-1 drugs and 5 among those on placebo, with none in patients taking other glucose-lowering drugs. That works out to 6.4 cases per 100,000 person-years with GLP-1 treatment versus 3.8 with comparators, the agency said.

The absolute numbers are small, and CNBC noted that a causal relationship has not been established. The FDA also pointed out that published estimates put NAION incidence in the general population at 2.3 to 10.2 cases per 100,000 adults over 50 each year.

What the FDA is telling patients and clinicians

The agency listed symptoms to watch for, including sudden vision loss in one eye that may be noticed on waking, blind spots or tunnel vision, color distortion and blurry central vision, and advised patients to contact a health care professional right away if these occur. It named possible risk factors such as smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. Clinicians are advised to refer suspected cases promptly to an ophthalmologist and to consider stopping the GLP-1 drug in patients who develop NAION, unless the benefits clearly outweigh the risk.

What this means for readers

For most people taking a GLP-1 medicine, the FDA's figures describe a rare event, and the agency's advice centers on recognizing symptoms and acting quickly rather than on stopping treatment across the board. The practical step is to know the warning signs, treat any sudden change in vision in one eye as urgent, and mention a past NAION episode or eye condition to the prescriber before starting or continuing one of these drugs.

#semaglutide#tirzepatide#fda#naion#label change#eye safety
This article is for general information only and is not medical advice. Consult a licensed healthcare provider before making any decisions about GLP-1 medications.